Literature DB >> 7308179

Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate.

L C Costello, R B Franklin.   

Abstract

Aconitase activity and citrate oxidation were determined in mitochondrial preparations from rat ventral prostate. Aconitase activity in prostate mitochondria was approximately 10% of the activity observed in kidney preparations. The prostate aconitase activity was completely inhibited by the addition of 1.0 mmol/l zinc and kidney aconitase was inhibited by approximately 50%. The presence of 1.0 mmol/l zinc also markedly inhibited the formation of isocitrate from cis-aconitate. The reduction of NADP by citrate was markedly inhibited (approx. 95%) by 1.0 mmol/l zinc as compared with a 70 and 40% inhibition of aconitate--and isocitrate--stimulated reduction, respectively. These results indicate that zinc might be a strong inhibitor of aconitase activity with an inhibitory effect on isocitrate dehydrogenase also. The effect of 1.0 mmol/l zinc on citrate oxidation was studied by determining 14CO2 production from 6-14C-citrate. 14CO2 was significantly inhibited by zinc. These results further corroborate the conclusion that citrate accumulation in prostate might be the result of limited citrate oxidation which results from a combination of low aconitase activity and possibly zinc inhibition.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308179     DOI: 10.1159/000459195

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  18 in total

Review 1.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer.

Authors:  L C Costello; R B Franklin; Pei Feng
Journal:  Mitochondrion       Date:  2005-06       Impact factor: 4.160

Review 2.  Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology.

Authors:  Peter Swindle; Saadallah Ramadan; Peter Stanwell; Simon McCredie; Peter Russell; Carolyn Mountford
Journal:  MAGMA       Date:  2008-09-17       Impact factor: 2.310

Review 3.  A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Arch Biochem Biophys       Date:  2016-04-27       Impact factor: 4.013

4.  Inhibition of prostate cancer proliferation by Deferiprone.

Authors:  Rui V Simões; Suresh Veeraperumal; Inna S Serganova; Natalia Kruchevsky; Joseph Varshavsky; Ronald G Blasberg; Ellen Ackerstaff; Jason A Koutcher
Journal:  NMR Biomed       Date:  2017-03-08       Impact factor: 4.044

5.  Multi-parametric MR imaging of transition zone prostate cancer: Imaging features, detection and staging.

Authors:  Arda Kayhan; Xiaobing Fan; Jacob Oommen; Aytekin Oto
Journal:  World J Radiol       Date:  2010-05-28

6.  Regulation of citrate metabolism by androgen in the LNCaP human prostate carcinoma cell line.

Authors:  R B Franklin; H H Juang; J Zou; L C Costello
Journal:  Endocrine       Date:  1995-08       Impact factor: 3.633

7.  Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate.

Authors:  M Veronica Clavijo Jordan; Su-Tang Lo; Shiuhwei Chen; Christian Preihs; Sara Chirayil; Shanrong Zhang; Payal Kapur; Wen-Hong Li; Luis M De Leon-Rodriguez; Angelo J M Lubag; Neil M Rofsky; A Dean Sherry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

8.  Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells.

Authors:  R B Franklin; J Ma; J Zou; Z Guan; B I Kukoyi; P Feng; L C Costello
Journal:  J Inorg Biochem       Date:  2003-08-01       Impact factor: 4.155

9.  Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells.

Authors:  Y Liu; L C Costello; R B Franklin
Journal:  Metabolism       Date:  1996-04       Impact factor: 8.694

Review 10.  Tumour metabolism and its unique properties in prostate adenocarcinoma.

Authors:  David A Bader; Sean E McGuire
Journal:  Nat Rev Urol       Date:  2020-02-28       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.